Home >

Welcome to Molecular Oncology Tumor Boards

The Molecular Oncology Tumor Boards are a series of bi-monthly, user-driven discussions designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. Moderated by an expert pathologist and medical oncologist, each case will be updated with new information over a 2-week period as user comments are added. Sign in with your ASCO username and password to participate. After 2 weeks, the discussion will be locked to further commentary and users will be able to claim CME credit for their participation. Visit ASCO University to learn more. 

To participate in discussions on other oncology-related topics, visit ASCO’s member community on myConnection. Connect with colleagues, build your professional network, exchange ideas, collaborate, and more

LOGIN TO START A DISCUSSION
Molecular Oncology Tumor Board
ASCO University
Oct 12, 2016 9:33 AM
Read more to answer the following questions: Who should get routine molecular testing at diagnosis for NSCLC and what tests should be performed? What is the most appropriate initial treatment for this patient?
Molecular Oncology Tumor Board
ASCO University
Sep 14, 2016 8:48 AM
Read more to answer the following questions:
What pathologic features are frequently associated with MSI-H colorectal cancers? What are the NCCN guidelines for Lynch syndrome screening in patients with colorectal cancer or endometrial cancer?
Molecular Oncology Tumor Board
ASCO University
Aug 10, 2016 9:13 AM
Read more to answer the following questions:
Evaluate the appropriate work up and treatment for HPV-related head and neck cancer
Analyze the interpretation and limitations of p16 staining as a surrogate marker for HPV
Identify the work up and treatment for a head and neck cancer of unknown primary
Molecular Oncology Tumor Board
ASCO University
Jul 13, 2016 9:27 AM
Read more to answer the following questions:

According to WHO 2016 criteria, what is the most accurate diagnosis and how do we distinguish ET from PMF in era of molecular studies? Does it matter to distinguish early primary myelofibrosis from essential thrombocythemia for management?
How would we...
Molecular Oncology Tumor Board
ASCO University
Jun 15, 2016 8:26 AM
Read more to answer the following questions: 1) What is the significance of the patient having only a partial resection of an ologodendroglioma? 2) What is the importance of the 1p19q co-deletion status of the tumor?

Pages


Advertisement